How Four Drugs Beat Heart Failure
Hosted by Sarah Mitchell & James Carter
Show Notes
Four drug classes — ARNi, beta-blocker, MRA, SGLT2 inhibitor — have together produced a 73% reduction in cardiovascular death and hospitalisation versus placebo in HFrEF. Sarah Mitchell and James Carter unpack why each drug works, what the landmark trials showed, and why clinical inertia is still the biggest barrier to optimal care.
Downloads
Cite This Article
Team TLSFE. How four drugs beat heart failure. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/podcast/2026-06-01/how-four-drugs-beat-heart-failure.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Podcast Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
More from: Heart Failure Deep Dive Series
Diabetes Drugs For Stiff Heart Failure
Heart failure with preserved ejection fraction accounts for more than half of all HF diagnoses. For two decades every major drug trial failed. Then SGLT2 inhibitors changed everything - twice. Sarah Mitchell and James Carter explain why HFpEF was so hard, and what finally worked.
Semaglutide For Obese Heart Failure Patients
More than 80% of HFpEF patients are overweight or obese. STEP-HFpEF showed semaglutide 2.4mg improved symptoms by 16 points on the KCCQ and reduced weight by 13.3% - now a Class IIa ESC recommendation. Sarah Mitchell and James Carter explore why treating the metabolic environment is the new paradigm for HFpEF.
Managing Acute Heart Failure And Cardiogenic Shock
Acute decompensated heart failure drives over one million hospital admissions annually. 30-day readmission rates are 25%. When the heart cannot compensate, the tools change entirely - IV diuretics, inotropes, mechanical circulatory support. Sarah Mitchell and James Carter cover ADHF management, cardiogenic shock, and how to prevent the revolving door.